Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGA111 for Degenerative Lumbar Disc Disease (Phase II)
CTR20201811Phase 2Completed
- Sponsor
- Angitia Biopharmaceuticals
- Start
- Sep 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of AGA111 in degenerative disc disease (DDD), sponsored by Angitia Biopharmaceuticals. Started Sep 2020; status: completed.
02
Drugs
AGA111
03
Conditions
degenerative disc disease (DDD)
Beyond the preview
Go deeper on CTR20201811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201811.